Technical Analysis for ZLAB - Zai Lab Limited

Grade Last Price % Change Price Change
grade C 26.31 -1.76% -0.47
ZLAB closed down 1.76 percent on Friday, May 24, 2019, on 57 percent of normal volume.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical ZLAB trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Inside Day Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -1.76%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.54%
20 DMA Support Bullish -4.54%
Inside Day Range Contraction -4.54%
Crossed Above 20 DMA Bullish -5.93%
NR7 Range Contraction -2.19%
NR7-2 Range Contraction -2.19%

Older signals for ZLAB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Biopharmaceutical Pharmaceutical Industry Natural Sciences Medication
Is ZLAB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 16 Zai Lab on go with China study of antibiotic combo
May 16 Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections
May 9 Zai Lab Announces Participation at Upcoming May Conferences
May 4 Here’s What Hedge Funds Think About Zai Lab Limited (ZLAB)
May 3 OLED, MELI among premarket gainers
May 3 Zai Lab prices upsized equity offering; shares up 2% premarket
May 2 Zai Lab Announces Pricing of Public Offering of American Depositary Shares
May 2 Zai Lab launches equity offering
May 1 3 Top Chinese Stocks to Watch in May
May 1 Zai Lab Announces Proposed Public Offering of American Depositary Shares
See more ZLAB news...
Indicators
Indicator Value
52 Week High 33.86
52 Week Low 14.29
Average Volume 198,692
200-Day Moving Average 23.6446
50-Day Moving Average 28.8376
20-Day Moving Average 27.2705
10-Day Moving Average 27.407
Average True Range 1.2289
ADX 25.96
+DI 15.5109
-DI 28.3525
Chandelier Exit (Long, 3 ATRs ) 25.3733
Chandelier Exit (Short, 3 ATRs ) 27.1017
Upper Bollinger Band 28.7879
Lower Bollinger Band 25.7531
Percent B (%b) 0.18
BandWidth 11.128509
MACD Line -0.4854
MACD Signal Line -0.4528
MACD Histogram -0.0326
Fundamentals Value
Market Cap 1.29 Billion
Num Shares 49.1 Million
EPS -4.94
Price-to-Earnings (P/E) Ratio -5.33
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.33
Resistance 3 (R3) 27.42 27.16 27.16
Resistance 2 (R2) 27.16 26.90 27.12 27.10
Resistance 1 (R1) 26.74 26.74 26.61 26.65 27.05
Pivot Point 26.48 26.48 26.42 26.44 26.48
Support 1 (S1) 26.06 26.22 25.93 25.97 25.57
Support 2 (S2) 25.80 26.06 25.76 25.52
Support 3 (S3) 25.38 25.80 25.46
Support 4 (S4) 25.29